Custom Search


Wednesday 01 December 2004

Ziprasidone for agitation or psychosis in dementia: four cases.

By: Cole SA, Saleem R, Shea WP, Sedler M, Sablosky M, Jyringi D, Smith A.

Int J Psychiatry Med 2005;35(1):91-8

OBJECTIVE: These case reports examine the potential efficacy and safety of ziprasidone for the treatment of agitation or psychosis in dementia. METHOD: The authors performed a retrospective chart review of three patients with DSM-IV diagnoses of dementia, treated with ziprasidone for agitation/psychosis on an academic psychiatric inpatient unit in 2002-2003. In addition, these three case reports are supplemented by a clinical report of the first outpatient with DSM-IV diagnosis of dementia completing a prospective open-label six-week study in 2004 evaluating the use of oral ziprasidone for agitation/psychosis in dementia. Qualitative descriptions of clinical improvement provide outcome data for these case reports. RESULTS: Four patients with dementia with agitation/psychosis experienced marked behavioral improvement after receiving oral doses of ziprasidone (20-160 mg/day), without any evidence of problematic cardiac or other side-effects. Two of the four patients had final EKGs and both of these patients demonstrated no change of QTc interval after administration of ziprasidone. CONCLUSIONS: These case reports suggest that oral ziprasidone may be an effective and safe medication for the treatment of agitation or psychosis in patients with dementia.

Use of this site is subject to the following terms of use